Intravenous Acetaminophen to Reduce Post-operative Opioid Consumption

Trial statusNot yet recruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18+
SponsorCentre hospitalier de l'Université de Montréal (CHUM)

About this trial

Acetaminophen (Tylenol) is a commonly used medication after surgery to control pain. Tablets for oral use and suppositories for rectal use are the most frequently employed forms of acetaminophen after surgery. Intravenous (IV) acetaminophen is widely used in several countries but is not a standard medication for the adult population in Canada. It is mainly considered when it is impossible to take medication in tablet or suppository form. Opioids (Morphine, Hydromorphone, Oxycodone, etc.) are another class of medications commonly used after surgery for pain management. While they are generally very effective and stronger than acetaminophen or other pain relievers (e.g., ibuprofen/Advil), reducing their use is preferable, as they can cause various side effects such as nausea, dizziness, and dependence. IV acetaminophen may help control pain while also reducing opioid consumption. However, there are few high-quality scientific studies proving the benefits of IV acetaminophen compared to other forms, such as tablets or suppositories. Acetaminophen has been available in Canada for many years and has already been recommended for use in Quebec by the Institut national d'excellence en santé et services sociaux (INESSS) under certain conditions. This study aims to validate its benefits with clear data.

Eligibility criteria

Qualifiers

Age 18 years or older.

Underwent abdominal surgery

Underwent elective surgery.

Hospitalized in the digestive surgery, hepatobiliary and pancreatic surgery, or gynecology and gynecologic oncology units at CHUM.

Disqualifiers

Hypersensitivity to acetaminophen or an excipient in the administered formulations

Hepatic insufficiency with a Child-Turcotte-Pugh score of B or C.

Weight < 50 kg (patients requiring a lower acetaminophen dose).

Active pregnancy or breastfeeding.

Trial design

Treatments tested in this trial

  • IV Acetaminophen

Treatment groups

140 Participants
are divided into 2 treatment groups